D-penicillamine Induced Myasthenia Gravis in Wilson's Disease: A Case Report

Overview

Journal JNMA J Nepal Med Assoc

Specialty General Medicine

Date 2023 Jan 27

PMID 36705187

Authors

Lekhjung Thapa

Monika Thapa

Suman Bhattarai

Abhishek Man Shrestha

Nooma Sharma

Nilshan Rai

Merina Pokharel

Raju Paudel

Affiliations

Soon will be listed here.

Abstract

Keywords: d-penicillamine; myasthenia gravis; pyridostigmine; Wilson's disease.

Citing Articles

Wilson's Disease-Crossroads of Genetics, Inflammation and Immunity/Autoimmunity: Clinical and Molecular Issues.

Gromadzka G, Czerwinska J, Krzeminska E, Przybylkowski A, Litwin T Int J Mol Sci. 2024; 25(16).

PMID: 39201720 PMC: 11354778. DOI: 10.3390/ijms25169034.

D-Penicillamine-Induced Myasthenia Gravis-A Probable Complication of Wilson's Disease Treatment-A Case Report and Systematic Review of the Literature.

Antos A, Czlonkowska A, Bembenek J, Kurkowska-Jastrzebska I, Litwin T Life (Basel). 2023; 13(8).

PMID: 37629572 PMC: 10455431. DOI: 10.3390/life13081715.

References

Gummi R, Kukulka N, Deroche C, Govindarajan R . Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019; 60(6):693-699. DOI: 10.1002/mus.26689. View

Varghese T, Ahmed R, Sankaran J, Al-Khusaiby S . D-Penicillamine induced myasthenia gravis. Neurosciences (Riyadh). 2013; 7(4):293-5. View

Johnson S, Katyal N, Narula N, Govindarajan R . Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis. Med Sci Monit. 2021; 27:e933296. PMC: 8562011. DOI: 10.12659/MSM.933296. View

Katz L, Lesser R, Merikangas J, Silverman J . Ocular myasthenia gravis after D-penicillamine administration. Br J Ophthalmol. 1989; 73(12):1015-8. PMC: 1041959. DOI: 10.1136/bjo.73.12.1015. View

Hill M, Moss P, Wordsworth P, Newsom-Davis J, Willcox N . T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. J Neuroimmunol. 1999; 97(1-2):146-53. DOI: 10.1016/s0165-5728(99)00038-7. View

Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J . Myasthenia gravis: a review. Autoimmune Dis. 2012; 2012:874680. PMC: 3501798. DOI: 10.1155/2012/874680. View

Leite M, Jones M, Strobel P, Marx A, Gold R, Niks E . Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol. 2007; 171(3):893-905. PMC: 1959483. DOI: 10.2353/ajpath.2007.070240. View

Rousseff R . Diagnosis of Myasthenia Gravis. J Clin Med. 2021; 10(8). PMC: 8073361. DOI: 10.3390/jcm10081736. View

Benatar M . A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006; 16(7):459-67. DOI: 10.1016/j.nmd.2006.05.006. View

10.

Vincent A, Palace J, Hilton-Jones D . Myasthenia gravis. Lancet. 2001; 357(9274):2122-8. DOI: 10.1016/S0140-6736(00)05186-2. View

11.

Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos S . Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012; 250(1-2):94-8. DOI: 10.1016/j.jneuroim.2012.05.011. View

12.

Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P . Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021; 19(1):516. PMC: 8686543. DOI: 10.1186/s12967-021-03185-7. View